Key Takeaways Mounjaro contains tirzepatide , a dual GIP and GLP-1 receptor agonist, while Wegovy contains semaglutide , a single GLP-1 receptor agonist Mounjaro generally produces stronger results in body composition management compared to Wegovy in head-to-head studies Both medications work by reducing appetite and helping you feel fuller for longer, supporting metabolic health goals UK clinic costs are prohibitive : Mounjaro typically costs 300+ monthly, Wegovy around 250+ monthly through private providers Affordable tirzepatide alternatives exist : Tirzeparo offers the same active ingredient at 169-229 monthly with discreet EU delivery Dosing schedules differ : Mounjaro starts at 2.5mg weekly and increases gradually
Format: Research-grade synthetic peptide supplied as a lyophilized powder
Navigating insurance coverage for Tirzepatide, a medication approved for weight management, requires understanding the specific criteria set by insurance plans and the acceptance under government programs like Medicare and Medicaid
Clinicians should recognize that while the preclinical data is encouraging, prescribing tirzepatide for neuroprotection is investigational and not supported by FDA-approved indications
But "can" and "always do" are different things entirely
Then 10mg
.png)
